Esketamine (CLE-100) vs Zelquistinel
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Major Depressive Disorder
Shared mechanism: NMDA receptor · full Major Depressive Disorder pipeline
Esketamine (CLE-100)
Developed by Clexio Biosciences
NCT04103892 · Phase 2 · completed
The study randomized 146 participants overall, including 130 in the main Part B comparison, to double-blind CLE-100 or placebo alongside standard antidepressant treatment. Its clinical MADRS primary endpoint was missed: the improvement with CLE-100 was not significantly different from placebo (p=0.46), so the trial provides well-controlled but inconclusive evidence.
Reported efficacy
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Score (29 days): Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Score (29 days): CLE-100 -11.66 units on a scale (Standard Error 1.5) vs Placebo -8.7 units on a scale (Standard Error 1.55) (missed)
Result source: NCT06340958
Zelquistinel
Developed by Syndeio Biosciences
NCT03726658 · Phase 1/2 · completed
The study randomized 226 participants overall to several zelquistinel dose groups or placebo and masked both participants and investigators, but it stated that no power calculation was performed and each comparison was relatively small. The primary MADRS comparisons were clinical measures but were missed, with all reported p-values above 0.05, so the findings provide limited evidence of benefit.
Next expected readout: September 2027 · NCT06547489 (registry estimate)
Reported efficacy
Part A: Change in MADRS Score at 1 Day the Initial Dose of AGN-241751 Reported as Change From Baseline in Treated Group Compared With Change From Baseline in Placebo Group (Baseline (Day1) to Day 2); Part B: Change From Baseline in MADRS Score at Day 8 Post the Initial Dose of AGN-241751 (i.e. 1 Day After the Seventh Daily Dose) (Baseline (Day 1) to Day 8): Part A: Change in MADRS Score at 1 Day the Initial Dose of AGN-241751 Reported as Change From Baseline in Treated Group Compared With Change From Baseline in Placebo Group (Baseline (Day1) to Day 2): AGN-241751 3mg Daily -9.4 score on a scale (Standard Error 1.57) | AGN-241751 10mg Daily -6.7 score on a scale (Standard Error 1.58) | AGN-241751 25mg Daily -9.5 score on a scale (Standard Error 1.57) vs Placebo Daily -9.3 score on a scale (Standard Error 1.61) (missed)
Result source: NCT03726658
Results for Major Depressive Disorder
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Esketamine (CLE-100) | Zelquistinel |
|---|---|---|
| MADRS, change (acute) | -10.7 vs -9.5−1.3 vs placeboNCT041038922 other results
| -10.5 vs -10.9+0.4 vs placeboNCT0372665825 other results
|
| CGI-S, change (acute) | —Not reported | —Not reported |
| MADRS response | —Not reported | —Not reported |
| MADRS remission | —Not reported | —Not reported |
| Relapse (% of patients) | —Not reported | —Not reported |
MADRS, change (acute)
- Esketamine (CLE-100)
- -10.7 vs -9.5−1.3 vs placeboNCT04103892
2 other results
- -11.7 vs -8.7 NCT06340958
- -13.0 vs -7.7 NCT04103892
- Zelquistinel
- -10.5 vs -10.9+0.4 vs placeboNCT03726658
25 other results
- -9.5 vs -9.3 NCT03726658
- -6.7 vs -9.3 NCT03726658
- -12.8 vs -10.9 NCT03726658
- -9.4 vs -9.3 NCT03726658
- -14.5 vs -13.6 NCT03726658
- -16.5 vs -16.5 NCT03726658
- -15 vs -16.9 NCT03726658
- -13.2 vs -11.6 NCT03726658
- -15.3 vs -14.7 NCT03726658
- -15.2 vs -14 NCT03726658
- -14.1 vs -12 NCT03726658
- -11.8 vs -13.6 NCT03726658
- -13.7 vs -11.6 NCT03726658
- -13.6 vs -12 NCT03726658
- -12.5 vs -13.6 NCT03726658
- -17.3 vs -16.5 NCT03726658
- -18.3 vs -16.9 NCT03726658
- -13.2 vs -11.6 NCT03726658
- -17 vs -14.7 NCT03726658
- -15.8 vs -14 NCT03726658
- -13 vs -12 NCT03726658
- -11.5 vs -13.6 NCT03586427
- -12.5 vs -13.6 NCT03586427
- -14.1 vs -13.6 NCT03586427
- -13.5 vs -13.6 NCT03586427
CGI-S, change (acute)
- Esketamine (CLE-100)
- —Not reported
- Zelquistinel
- —Not reported
MADRS response
- Esketamine (CLE-100)
- —Not reported
- Zelquistinel
- —Not reported
MADRS remission
- Esketamine (CLE-100)
- —Not reported
- Zelquistinel
- —Not reported
Relapse (% of patients)
- Esketamine (CLE-100)
- —Not reported
- Zelquistinel
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Esketamine (CLE-100): 4 of 4 rows · Zelquistinel: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Esketamine (CLE-100) | Zelquistinel |
|---|---|---|
| Dropout rate | 7.7%Part A - CLE-100 (Oral Esketamine) NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 show 2 more results8.3%Part B - CLE-100 (Oral Esketamine) NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 20% NCT06340958 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 | 7.7%25mg Dailya NCT03726658 · Phase 1/2 · monotherapy show 8 more results12.5%25mg Two Times Per Day NCT03726658 · Phase 1/2 · monotherapy 0%10mg Daily NCT03726658 · Phase 1/2 · monotherapy 3.8%3mg Daily NCT03726658 · Phase 1/2 · monotherapy 15%3mg Two Times Per Day NCT03726658 · Phase 1/2 · monotherapy 0%AGN-241751 Dose 1 NCT03586427 · Phase 2 · registry result, not featured evidence 8%AGN-241751 Dose 2 NCT03586427 · Phase 2 · registry result, not featured evidence 11.5%AGN-241751 Dose 3 NCT03586427 · Phase 2 · registry result, not featured evidence 8%AGN-241751 Dose 4 NCT03586427 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 0%Part A - CLE-100 (Oral Esketamine) NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 show 2 more results0%Part B - CLE-100 (Oral Esketamine) NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 8% NCT06340958 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 | —25mg Dailya NCT03726658 · Phase 1/2 · monotherapy show 8 more results—25mg Two Times Per Day NCT03726658 · Phase 1/2 · monotherapy —10mg Daily NCT03726658 · Phase 1/2 · monotherapy —3mg Daily NCT03726658 · Phase 1/2 · monotherapy —3mg Two Times Per Day NCT03726658 · Phase 1/2 · monotherapy 0%AGN-241751 Dose 1 NCT03586427 · Phase 2 · registry result, not featured evidence 0%AGN-241751 Dose 2 NCT03586427 · Phase 2 · registry result, not featured evidence 1.9%AGN-241751 Dose 3 NCT03586427 · Phase 2 · registry result, not featured evidence 0%AGN-241751 Dose 4 NCT03586427 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 0%Part A - CLE-100 (Oral Esketamine) NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 show 2 more results0%Part B - CLE-100 (Oral Esketamine) NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 2% NCT06340958 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 | 0%25mg Dailya NCT03726658 · Phase 1/2 · monotherapy show 8 more results0%25mg Two Times Per Day NCT03726658 · Phase 1/2 · monotherapy 0%10mg Daily NCT03726658 · Phase 1/2 · monotherapy 0%3mg Daily NCT03726658 · Phase 1/2 · monotherapy 0%3mg Two Times Per Day NCT03726658 · Phase 1/2 · monotherapy 0%AGN-241751 Dose 1 NCT03586427 · Phase 2 · registry result, not featured evidence 0%AGN-241751 Dose 2 NCT03586427 · Phase 2 · registry result, not featured evidence 0%AGN-241751 Dose 3 NCT03586427 · Phase 2 · registry result, not featured evidence 0%AGN-241751 Dose 4 NCT03586427 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | dizziness 30.8% (placebo 0%) somnolence 15.4% (placebo 0%) alanine aminotransferase increased 7.7% (placebo 0%) NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 show 2 more resultsdizziness 13.9% (placebo 0%) headache 12.5% (placebo 0%) somnolence 11.1% (placebo 0%) NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 dizziness 18% (placebo 4.1%) nausea 18% (placebo 0%) headache 12% (placebo 2%) NCT06340958 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2 | 25mg Dailya headache 15.4% (placebo 34.1%) nausea 7.7% (placebo 4.9%) abnormal dreams 0% (placebo 4.9%) NCT03726658 · Phase 1/2 · monotherapy show 8 more results25mg Two Times Per Day headache 24.4% (placebo 34.1%) nausea 14.6% (placebo 4.9%) abnormal dreams 4.9% (placebo 4.9%) NCT03726658 · Phase 1/2 · monotherapy 10mg Daily headache 19.2% (placebo 34.1%) nausea 11.5% (placebo 4.9%) abnormal dreams 0% (placebo 4.9%) NCT03726658 · Phase 1/2 · monotherapy 3mg Daily headache 15.4% (placebo 34.1%) nausea 7.7% (placebo 4.9%) abnormal dreams 0% (placebo 4.9%) NCT03726658 · Phase 1/2 · monotherapy 3mg Two Times Per Day headache 14.6% (placebo 34.1%) abnormal dreams 7.3% (placebo 4.9%) back pain 7.3% (placebo 2.4%) NCT03726658 · Phase 1/2 · monotherapy headache 6.3% (placebo 7.8%) diarrhea 4.2% (placebo 0%) dizziness 4.2% (placebo 3.9%) NCT03586427 · Phase 2 · registry result, not featured evidence insomnia 10% (placebo 2%) headache 6% (placebo 7.8%) nausea 6% (placebo 3.9%) NCT03586427 · Phase 2 · registry result, not featured evidence anxiety 5.8% (placebo 0%) dizziness 5.8% (placebo 3.9%) headache 5.8% (placebo 7.8%) NCT03586427 · Phase 2 · registry result, not featured evidence dizziness 6% (placebo 3.9%) dry mouth 6% (placebo 2%) abnormal dreams 4% (placebo 0%) NCT03586427 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Esketamine (CLE-100)'s landscape · Zelquistinel's landscape